Related Experiment Video

Updated: Jun 20, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Epidermal growth factor receptor-regulated miR-125a-5p--a metastatic inhibitor of lung cancer

Guofu Wang1, Weimin Mao, Shu Zheng

  • 1Department of Respiratory Disease, Zhejiang Hospital, Hangzhou, China.

The FEBS Journal
|August 26, 2009
PubMed

Insights

MicroRNA-125a-5p, a regulator of epidermal growth factor receptor signaling, suppresses lung cancer cell migration and invasion. Its repression correlates with lung carcinogenesis, suggesting a role as a metastatic suppressor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial in lung cancer progression.
  • MicroRNAs (miRNAs) are key regulators of gene expression implicated in cancer development.

Purpose of the Study:

  • To investigate the role of miRNAs in EGFR signaling in lung cancer.
  • To identify specific miRNAs regulated by EGFR signaling and their functional impact.

Main Methods:

  • miRNA array analysis to identify downstream targets of EGFR signaling.
  • Cell migration and invasion assays to assess functional effects of identified miRNAs.
  • Analysis of downstream gene expression regulated by EGFR signaling.
  • Correlation analysis of miRNA expression in lung cancer patient samples.

Main Results:

  • miR-125a-5p was identified as a downstream target of EGFR signaling.
  • miR-125a-5p significantly inhibited lung cancer cell migration and invasion.
  • miR-125a-5p modulated the expression of several EGFR signaling pathway genes.
  • Repression of miR-125a-5p was significantly correlated with lung carcinogenesis.

Conclusions:

  • miR-125a-5p is regulated by EGFR signaling and acts as a suppressor of lung cancer metastasis.
  • This miRNA represents a potential therapeutic target for inhibiting lung cancer progression.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...